Literature DB >> 18642851

DNA polymerases as therapeutic targets.

Anthony J Berdis1.   

Abstract

Numerous pathological states, including cancer, autoimmune diseases, and viral/bacterial infections, are often attributed to uncontrollable DNA replication. Inhibiting this essential biological process provides an obvious therapeutic target against these diseases. A logical target is the DNA polymerase, the enzyme responsible for catalyzing the addition of mononucleotides to a growing polymer using a DNA or RNA template as a guide for directing each incorporation event. This review provides a summary of therapeutic agents that target polymerase activity. A discussion of the biological function and mechanism of polymerases is first provided to illustrate the strategy for therapeutic intervention as well as the rational design of various nucleoside analogues that inhibit various polymerases associated with viral infections and cancer. The development of nucleoside and non-nucleoside inhibitors as antiviral agents is discussed with particular emphasis on their mechanism of action, structure-activity relationships, toxicity, and mechanism of resistance. In addition, commonly used anticancer agents are described to illustrate the similarities and differences associated with various nucleoside analogues as therapeutic agents. Finally, new therapeutic approaches that include the inhibition of selective polymerases involved in DNA repair and/or translesion DNA synthesis as anticancer agents are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18642851      PMCID: PMC2692436          DOI: 10.1021/bi801179f

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  54 in total

1.  Kinetic characterization of the polymerase and exonuclease activities of the gene 43 protein of bacteriophage T4.

Authors:  T L Capson; J A Peliska; B F Kaboord; M W Frey; C Lively; M Dahlberg; S J Benkovic
Journal:  Biochemistry       Date:  1992-11-17       Impact factor: 3.162

Review 2.  Mutagenicity of a unique apurinic/apyrimidinic site in mammalian cells.

Authors:  A Gentil; J B Cabral-Neto; R Mariage-Samson; A Margot; J L Imbach; B Rayner; A Sarasin
Journal:  J Mol Biol       Date:  1992-10-20       Impact factor: 5.469

Review 3.  Conformational coupling in DNA polymerase fidelity.

Authors:  K A Johnson
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

4.  Lethal mutagenesis of HIV with mutagenic nucleoside analogs.

Authors:  L A Loeb; J M Essigmann; F Kazazi; J Zhang; K D Rose; J I Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

5.  Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.

Authors:  S S Yang; V Fliakas-Boltz; J P Bader; R W Buckheit
Journal:  Leukemia       Date:  1995-10       Impact factor: 11.528

6.  Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.

Authors:  S G Kerr; K S Anderson
Journal:  Biochemistry       Date:  1997-11-18       Impact factor: 3.162

7.  Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism.

Authors:  P R Meyer; S E Matsuura; A G So; W A Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

8.  Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs.

Authors:  Z Gu; E J Arts; M A Parniak; M A Wainberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

Authors:  R A Spence; W M Kati; K S Anderson; K A Johnson
Journal:  Science       Date:  1995-02-17       Impact factor: 47.728

10.  Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers.

Authors:  M L Veigl; L Kasturi; J Olechnowicz; A H Ma; J D Lutterbaugh; S Periyasamy; G M Li; J Drummond; P L Modrich; W D Sedwick; S D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

View more
  38 in total

Review 1.  Targeting DNA polymerase ß for therapeutic intervention.

Authors:  Eva M Goellner; David Svilar; Karen H Almeida; Robert W Sobol
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

2.  Replication of the 2,6-diamino-4-hydroxy-N(5)-(methyl)-formamidopyrimidine (MeFapy-dGuo) adduct by eukaryotic DNA polymerases.

Authors:  Plamen P Christov; Kinrin Yamanaka; Jeong-Yun Choi; Kei-ichi Takata; Richard D Wood; F Peter Guengerich; R Stephen Lloyd; Carmelo J Rizzo
Journal:  Chem Res Toxicol       Date:  2012-07-06       Impact factor: 3.739

3.  Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus.

Authors:  Sophie Duraffour; Graciela Andrei; Dimitri Topalis; Marcela Krečmerová; Jean-Marc Crance; Daniel Garin; Robert Snoeck
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

4.  Participation of translesion synthesis DNA polymerases in the maintenance of chromosome integrity in yeast Saccharomyces cerevisiae.

Authors:  O V Kochenova; J V Soshkina; E I Stepchenkova; S G Inge-Vechtomov; P V Shcherbakova
Journal:  Biochemistry (Mosc)       Date:  2011-01       Impact factor: 2.487

5.  Targeting translesion synthesis to facilitate the eradication of ovarian cancer stem cells by platinum-based therapy.

Authors:  Amit Kumar Srivastava; Qi-En Wang
Journal:  Mol Cell Oncol       Date:  2015-06-02

6.  From bench to bedside: the growing use of translational research in cancer medicine.

Authors:  Erin M Goldblatt; Wen-Hwa Lee
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

7.  Enthalpy-entropy contribution to carcinogen-induced DNA conformational heterogeneity.

Authors:  Fengting Liang; Bongsup P Cho
Journal:  Biochemistry       Date:  2010-01-19       Impact factor: 3.162

8.  Microfluidic-assisted analysis of replicating DNA molecules.

Authors:  Julia M Sidorova; Nianzhen Li; David C Schwartz; Albert Folch; Raymond J Monnat
Journal:  Nat Protoc       Date:  2009-05-14       Impact factor: 13.491

9.  Bacteria under SOS evolve anticancer phenotypes.

Authors:  Shatha F Dallo; Tao Weitao
Journal:  Infect Agent Cancer       Date:  2010-02-05       Impact factor: 2.965

Review 10.  InTERTpreting telomerase structure and function.

Authors:  Haley D M Wyatt; Stephen C West; Tara L Beattie
Journal:  Nucleic Acids Res       Date:  2010-05-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.